Objective: Tumors and other disease complications of neurofibromatosis (NF) can cause pain and negatively affect physical functioning. To document the clinical benefit of treatment in NF trials targeting these manifestations, patient-reported outcomes (PROs) assessing pain and physical functioning should be included as study endpoints. Currently, there is no consensus on the selection and use of such measures in the NF population. This article presents the recommendations of the PRO group of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration for assessing the domains of pain and physical functioning for NF clinical trials.
pseudoarthrosis, and chest wall malformations, also may contribute to morbidity. 2 Furthermore, chronic pain is common in children 3, 4 and adults 5, 6 with neurofibromatosis (NF) and may be related to tumors, physical impairments, and headaches. 2, 3, 5, 6 These complications of NF can significantly affect physical functioning, activities of daily living, and quality of life (QOL). 4, 6 The number of clinical trials evaluating treatments for tumors and other manifestations of NF1, NF2, and SWN has increased over the last several years. To assess clinical benefit from the patients' perspective in drug trials, investigators have begun to incorporate patientreported outcome (PRO) measures as secondary endpoints. 7 Current behavioral intervention studies focusing on reducing pain and its interference with everyday functioning use PROs as primary endpoints. 8 PRO measures also can further define baseline disease characteristics 7 and document effects of drug toxicities. 9 Regulatory agencies in the United States and Europe recommend including PRO tools in clinical trials to systematically evaluate symptoms of interest 10, 11 as the data can provide complementary information about the efficacy of a new treatment. 10 To support medical product approval and labeling claims in the United States, PRO tools must be qualified by the Food and Drug Administration (FDA) as a clinical outcome assessment (COA) 12 and meet rigorous standards to be used as trial endpoints. 11 In meetings with Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) members, the FDA has indicated that COAs of pain and physical functioning need to be incorporated into trial design as coprimary or secondary endpoints to document clinical benefit in addition to tumor reduction for NF trials seeking drug approval.
Despite the increased interest in PROs, challenges remain in using such measures of pain and physical functioning in NF clinical trials. First, the complications of NF are heterogeneous and vary widely in prevalence and severity. 1, 13 Individuals often have multiple tumors and complications, making it difficult to differentiate changes in pain or functioning related to one particular tumor type or complication being treated in a clinical trial. Pain may be acute, episodic, or chronic, and vary in intensity and location. Thus, when designing an NF trial including pain PROs, researchers need to consider the frequency of evaluations, length of the response period (e.g., past 7 days), and how to track the locations of target tumors or complications in order to obtain reliable and valid assessments of pain throughout the study. Accurate recording of analgesic use also is required to help distinguish changes in pain related to tumor reduction due to the study drug from changes in pain due to analgesics. 14 In addition, NF complications, such as plexiform neurofibromas 3, 5 and learning disabilities, 15 are common in children through adults. Therefore, PRO measures used in NF trials must evaluate individuals across a wide range of ages and ability levels. To be feasible for multicenter and international studies, PRO tools need to be relatively brief, easy to administer, and available in different languages. Finally, no measures currently are validated to assess pain and physical functioning across the lifespan in NF, and there is a lack of consensus about how to assess PROs in NF clinical trials. The US FDA and European regulatory agencies have acknowledged the importance of developing a common core language and methodology for clinical trials evaluating new drugs that will permit comparisons of PROs across treatments. 10 To respond to these challenges and promote consensus in the assessment of PROs in NF clinical trials, the PRO group of the REiNS International Collaboration is working to provide guidance about appropriate PRO measures and methodologies in 4 core domains (pain, physical functioning, disease-specific QOL, and general QOL) for use in NF clinical trials. The PRO group's first publication 16 outlined their goals and described the systematic process they developed to review and choose PRO measures using pain intensity as an example. This article presents the current REiNS recommendations for the domains of pain and physical functioning, specifically focusing on self-report measures for ages 8 years and older and parent report questionnaires for 5 years and older.
METHODS The group's systematic method involves gathering information from extensive literature reviews and rating existing PRO measures on 6 criteria, as previously described. 16 PRO measures may be re-reviewed to consider new published data, and when scores are close, the highest-rated measures are compared directly during the same meeting. Of the 6 initial criteria, the group refined their focus to the 4 it deemed most important when making the final selection of a PRO measure 17 for NF clinical trials. Thus, patient characteristics, item content, psychometric properties, and feasibility for multicenter trials were the primary criteria used to determine the recommendations in the domains of pain and physical functioning. All the PRO measures reviewed for these domains are listed in table e-1 on the Neurology ® Web site at Neurology.org.
RESULTS Pain domain. Pain intensity recommendation.
The PRO group recommends the Numeric Rating Scale-11 (NRS-11) as a self-report measure of pain intensity (ages $8 years) for NF clinical trials, as described and compared in detail with other tools in our previous publication. 16 On the NRS-11, respondents are asked to circle the number from 0 (no pain) to 10 (e.g., worst pain imaginable) that best represents their pain. 18 The characteristics of the NRS-11 are shown in table 1.
Pain interference. In the domain of pain interference, our group initially identified 7 pain interference scales to consider. Of these, 4 met basic criteria to be suitable for use in NF clinical trials and were rated using our systematic process. The top-rated measures were the Pain Interference Index (PII), 19 Patient-Reported Outcome Measurement Information System Pain Interference scale (PROMIS-PI), 20 and Brief Pain Inventory Pain Interference subscale. 21 Our final side-by-side comparison resulted in the highest overall ratings, which were tied, for the PII and PROMIS-PI. Table 2 presents the characteristics of the PII and PROMIS-PI for each of the 4 main review criteria.
Pain Interference Index. The PII 19, 22 is a 6-item scale that assesses the extent to which pain has interfered with an individual's daily activities in the past 7 days. Items are rated on a 7-point Likert scale, and the total score is the mean of the completed items. The PII is suitable for NF clinical trials because it covers a wide age range, assesses areas relevant for NF, and has parallel child and adult self-report and parent proxy forms. Importantly for use in pediatric NF trials, the child and parent forms demonstrate good reliability and validity in NF1, 19 yield high correlations between parent and child scores, 19 and show sensitivity to change after behavioral interventions for chronic pain in children. 8 While good preliminary data exist in adults with NF1 (unpublished data) and other conditions involving pain, 23 more research is needed before recommending the adult version for NF trials.
Patient-Reported Outcome Measurement Information System
(PROMIS). PROMIS was created from an NIHsponsored initiative to develop standardized PRO measures that can be compared across patient populations and studies in a variety of health domains (http://www.nihpromis.org/). It utilizes Item Response Theory (IRT), in which each item in a large item bank is a measure of a latent trait that falls along a continuum. A small subset of these items are administered as short forms (SF) of various lengths (e.g., 8, 10, or 20 items) or as a computerized adaptive test (CAT), which selects the most relevant questions from an item bank based on a person's answers to previous questions, to produce brief and precise outcome assessments. 24, 25 Items are rated on a 5-point Likert scale, and the measures yield standardized T scores. PROMIS scales are appropriate for NF clinical trials because they assess relevant domains in a wide age range, have good psychometric properties, and are translated into multiple languages.
PROMIS-PI. The PROMIS-PI 20 assesses the degree to which pain has interfered with a patient's ability to complete daily activities over the past 7 days. This Table 1 Characteristics of the Numeric Rating Scale-11 (NRS-11) for the 4 main review criteria Criteria NRS-11 characteristics
Patient characteristics
Self-report form for $8 years 18, 40 Preliminary validity data for children 6-7 years 41 No published data using the NRS-11 in neurofibromatosis to date 16
Domains/item content Assesses pain intensity
Pain intensity rated from 0 (no pain) to 10 (worst pain you can imagine) over the past week
Different instructions and pain descriptors used 40
Psychometric data Good test-retest reliability for children (mean difference 0.2; 95% CI 0.0-0.4) 42 and adults (intraclass correlations 0.72-0.78) 43 Good construct validity supported by correlations with other pain intensity measures (e.g., NRS-11 and FPS-R, r 5 0.78) 18 Sensitive to change over time in children 42 and adults 43 Feasibility Free, brief, simple to administer Can be administered by paper/pencil, verbally, or electronically
Can modify descriptors and instructions
Available in multiple languages and can be translated
scale has demonstrated feasibility and validity in adults and youth with various medical conditions and chronic pain. 20, 26, 27 The PROMIS-PI also has been shown to be responsive to changes in pain in a limited number of clinical trials with adults 28 but not yet with children. 29 Published studies using both the pediatric selfreport and parent-proxy pain interference scales currently are scarce. The pediatric and parent forms are parallel and general parent-child agreement is moderate. 30 The item content and response options of the adult form are not consistent with the child/parent forms; thus, research is needed to evaluate whether these scales can provide a reliable assessment across age ranges for longitudinal studies involving children through adults. Studies investigating the self-report and parent-proxy versions in NF, including comparisons of CAT and SF administration in children, also are required before our group can recommend the PROMIS-PI for pediatric NF trials.
Pain interference recommendation. Since both of these pain interference tools have strengths and weaknesses for use in NF, the current REiNS recommendation is to utilize the PII in clinical trials involving children to young adults (6-24 years), the PROMIS-PI scale for adult trials ($18 years), and when possible, both measures for trials enrolling children through adults. Since there are limited publications using the PROMIS-PI in longitudinal studies and none with the NF population to date, the PRO group recommends administering the longest PI SF available (8 items) or both the 8-item SF and CAT in NF clinical trials to compare findings. Our group will review newly published data in the future to determine the one pain interference tool most suitable for NF clinical trials.
Physical functioning domain. In the domain of physical functioning, our group identified 6 PRO measures No test-retest reliability data to date Good test-retest reliability in adults (intraclass correlations 5 0.83-0.87) 26 ; lower in children (0.62) 35 Good correlation between child self-report and parent proxy scores (r 5 0.62, p , 0.0001) 19 in NF1/cancer Moderate agreement between child and parent PI scores (r 5 0.49) 30 Demonstrated construct validity based on correlation with established pain measures (r 5 0.81) and differentiates patients with varying levels of NF1 disease severity 19 Demonstrated construct validity with other PI scale (Spearman r 5 0.90) and known groups validity in adults 20 Responsive to change in children and adolescents after intervention 8 Known groups validity by disease severity for child self-report PI scale 27 ; no validity data for parent proxy to date Good preliminary psychometric data in adult patients 23 Responsive to change in adults 28 ; no changed detected in one pediatric longitudinal study to date 29 SF and CAT highly correlated; CAT often more precise than SF in adults 36 ; SF generally more precise than CAT in one pediatric study 35 appropriate for consideration; 5 met basic criteria to be rated. Of these, the PROMIS Physical Functioning scale (PROMIS-PF), 25 Health Assessment Questionnaire, 31 and Functional Disability Inventory 32 were the toprated measures. From our final side-by-side comparison of these 3 scales, the overall rating of the PROMIS-PF for use in NF clinical trials was the highest. Table 3 presents the characteristics of the PROMIS-PF for each of the 4 main review criteria. PROMIS-PF. The PROMIS-PF scale measures the perception of one's capability of performing specific physical activities. It includes items assessing upper extremity function, mobility (lower extremity), and, for adults, axial or head and neck function. 25 The PROMIS-PF demonstrates good reliability and construct validity in adults and youth from the general population and various disease groups. [25] [26] [27] [33] [34] [35] Adult studies show that the IRT-based PROMIS-PF scales reduce floor and ceiling effects, 36 are more accurate and efficient, decrease administration time, result in greater responsiveness, and require smaller study sample sizes than legacy PRO measures. 36, 37 Administration of the 10-item PROMIS-PF CAT to adults resulted in an efficient and precise measurement of physical functioning, which differentiated between age and disease groups. 36 However, in children with cerebral palsy, the PROMIS Mobility CAT did not correlate with performance measures or differentiate known mobility groups. 38 In clinical trials, the PROMIS-PF showed sensitivity to change after spine augmentation in adults 28 but not after surgery in children with cerebral palsy. 29 Physical functioning recommendation. Although published studies have not used the PROMIS-PF in NF to date, the evaluation of both upper and lower extremity function as well as the range, content, and wording of the items are well-suited to assess the spectrum of complications affecting physical function in NF. Therefore, the current REiNS recommendation is 
Psychometric data
Internal consistency excellent in adults with cancer (PF scale Cronbach a 5 0.92-0.96) 34 and moderate in children (SF upper extremity 5 0.62; mobility 5 0.73) 35 Good test-retest reliability of PF scale in adults with osteoarthritis (intraclass correlations 5 0.92 CAT; 0.95 SF) 26 and moderate in children (SF upper extremity 5 0.66; mobility 5 0.77) 35 Demonstrated construct validity with established measures (all rs . 0.68) and known groups validity in adults with cancer 34 Known groups validity by disease severity for child upper extremity and mobility PF scales 27 ; no validity data for parent proxy to date Good agreement between child self-report and parent proxy (upper extremity r 5 0.69; mobility r 5 0.63) 44 Sensitive to change after spine augmentation in adults 28 ; no change after surgery in children with cerebral palsy 29 CAT version less accurate then the SF in children with cerebral palsy 38 ; CAT was more precise than SF but CAT administered more items 35 Feasibility Brief, free, easy to administer to use the longest PF SF that is feasible for a particular study (e.g., 20-item SF was the most responsive in populations with physical impairments) 37 or the CAT in adult studies. The CAT alone is not recommended for pediatric studies at this time since it was less accurate than the SF in children with functional limitations. 38 When possible, giving both SF and CAT versions in pediatric NF studies will allow comparisons between the 2 versions to help refine these recommendations.
Recommendations for use of these measures for NF1, NF2, and SWN. The above recommendations on pain intensity, pain interference, and physical functioning PRO measures (listed in table 4) apply to clinical trials enrolling patients with NF1, NF2, or SWN. Each measure was evaluated for its ability to capture relevant changes in disease status regardless of the particular syndrome being studied (e.g., adequately measuring pain interference from plexiform neurofibromas in NF1 or from generalized chronic pain in SWN). Since the NRS-11, PII, PROMIS-PI, and PROMIS-PF assess generalized constructs rather than disease-specific manifestations of pain and disability, they are suited for a range of clinical trials in NF1, NF2, and SWN. However, the patient population and objectives of a particular clinical trial will dictate which of these PRO measures are most appropriate and whether additional measures may be needed to capture the full range of relevant PROs adequately. For example, a targeted measure on swallowing or breathing may be warranted for studies on plexiform tumors causing airway compression in NF1. Similarly, in trials for symptomatic vestibular schwannomas in NF2, targeted questionnaires on the effect of balance problems on physical activities or the effect of hearing decline on communicative ability may be warranted.
DISCUSSION PROs assessing pain and physical functioning are critical for documenting the clinical efficacy of treatments targeting manifestations of NF1, NF2, and SWN. The REiNS International Collaboration provides consensus recommendations regarding PROs to the NF research community based on extensive review of existing tools in these domains.
To assess pain intensity, the REiNS International Collaboration recommends the NRS-11 as a brief, reliable, and valid self-report scale to assess pain intensity for ages 8 years and older, as previously described. 16 However, for NF clinical trials targeting tumor reduction, research needs to explore modifications for assessing tumor-specific pain and indicating the location of the tumor pain being rated throughout a trial.
To assess pain interference, the current REiNS recommendation includes 2 measures until additional data are published to determine the most appropriate one for use in NF clinical trials across all age groups. At this time, the REiNS group recommends the PII for pediatric studies and the PROMIS-PI for adult trials. Both measures are recommended for NF studies including children and adults so the data can be compared. The PII is valid in children with NF1 and their parents 19 ; however, there currently are no published data in adults with NF1. The PROMIS-PI 20 is an IRT-based measure that has been used in several published studies with adults, has excellent feasibility, and has robust psychometric properties. However, additional research is needed to examine the use of the PROMIS-PI in children and parents, individuals with NF, and CAT in longitudinal studies.
In the domain of physical functioning, the REiNS Collaboration recommends the PROMIS-PF scale. 25 Although relatively new, the PROMIS-PF was deemed the most appropriate for NF clinical trials because it evaluates both upper and lower extremity functioning, consisting of a range of motor functions and daily living activities that are important to assess in NF. This scale should provide an efficient and precise PRO assessment of physical functioning and require smaller sample sizes, 37 which is important for clinical trials of rare diseases. However, CAT administration was not as accurate as the SF in children with functional limitations so both administration options need to be examined in the NF population. Additional information also is needed on the use of the pediatric scales over time. 27 Limitations. The continued work of the REiNS Collaboration and the broader scientific community will be important in addressing the current limitations associated with these recommendations. First is the challenge of whether these PRO tools accurately assess the specific types of pain and physical functions being evaluated in clinical trials for individuals with NF when multiple factors may contribute to their pain experience or impact their daily functioning. Another issue is the lack of data in NF1, NF2, and SWN and whether the psychometric properties of the scale in these conditions will be consistent with those documented in the general population. Additionally, no PRO tools to date have shown the ability to measure pain and physical functioning adequately for all ages. In particular, researchers need to address the evaluation of these domains in children under 8 years old since NF trials are enrolling these younger participants. This challenge is reflected in our recommendation of 2 pain interference scales, as currently there are insufficient published data for establishing the validity of either measure in children and adults with NF. Identifying the most appropriate methods to assess children with significant cognitive impairments also needs to be addressed. Our group will update our recommendations in these specific areas in future publications. To address the limitations noted above, PRO group members are using these recommended pain and physical functioning measures in descriptive studies and clinical trials with a wide age range of individuals who have all types of NF. Several of these PROs have been accepted into the FDA's Drug Development Tool COA Qualification Program 12 and are being further studied with both qualitative and quantitative research methods 11 to examine possible modifications and their use as NF clinical trial endpoints. The PRO working group also plans to form a subgroup that will focus on identifying measures to assess young children and individuals with significant cognitive impairments. Finally, researchers need to investigate the use of new methodologies in NF clinical trials to improve PRO data, such as using electronic administration to increase the accuracy and speed of data collection. 39 The REiNS PRO group is working to identify PRO measures that can be used consistently as endpoints across trials to assess clinical benefit of treatments to reduce tumors or other disease manifestations in individuals with NF1, NF2, and SWN. The REiNS recommendations for PROs in the domains of pain and physical functioning are presented with the understanding that further evaluation of the measures is needed in the NF population. Our group encourages researchers to use these PRO measures in upcoming NF studies. Final consensus recommendations regarding the one specific pain interference measure and format of the PROMIS-PF scales to use in NF clinical trials will be disseminated in a future publication based on results of additional published research.
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Comment: Clinical outcome assessments in transition
The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration systematically evaluated existing patientreported outcome (PRO) measures of pain intensity, pain interference, and physical functioning as potential primary and secondary outcomes for neurofibromatosis trials. On the basis of 4 criteria-patient characteristics, item content, psychometric properties, and feasibility-specific measures were recommended. 1 These recommendations are valuable for investigators designing clinical trials and can serve as a basis for developing improved outcome assessments for patients with these disorders.
In 2006, the US Food and Drug Administration (FDA) released a draft guidance on PRO measures that initiated a broader consideration of clinical outcome assessments (COAs) of "a patient's symptoms, overall mental state, or the effects of a disease or condition on how the patient functions." 2 COAs are used in evaluating efficacy and safety, and include patient-reported, clinician-reported, observerreported, and performance outcome measures. Such measures should be used within a carefully defined context of use for which available data provide support. 2 The FDA recently released a compendium of COAs that have either been used as a basis for regulatory decisions or are being developed in accord with its qualification program. 3 In evaluating COAs, the FDA examines their content validity (e.g., as assessed by patient focus groups and cognitive interviewing), reliability, construct validity, and longitudinal measurement properties (e.g., ability to detect change, responder criteria). 2 The REiNS recommendations were based on some of these characteristics, but most existing outcome measures fall short of the rigorous standards now being applied by the FDA. Indeed, as the REiNS investigators acknowledge, specification of the appropriate context of use (e.g., patient age, specific disorders) for pain and physical functioning measures in neurofibromatosis trials requires additional data. Systematic efforts to improve the validity, reliability, and responsiveness to change of COAs will ensure that clinical trial outcomes provide meaningful information about the treatment benefits and risks that patients consider most important.
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